1,4-Dihydro pyridine 3,5 dicarboxylic acid derivatives and compositions
US4806533A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Feb 19, 1987 |
| Grant date | Feb 21, 1989 |
| Priority date | — |
| Expiry date | Feb 19, 2007 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P9/00
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Compounds are described of the formula ##STR1## wherein R.sub.1 and R.sub.4 independently represent a C.sub.1-4 alkyl group; PA0 R.sub.2 and R.sub.3 independently represent a C.sub.1-6 straight or branched alkyl chain or alkoxy group; PA0 R.sub.5 represents a straight or branched chain C.sub.1-13 alkyl group or a C.sub.5-8 cycloalkyl group which may be substituted by a C.sub.1-3 alkyl substituent; PA0 R.sub.6 represents a halogen atom or a straight or branched C.sub.1-3 alkyl group. PA0 R.sub.7 represents a C.sub.1-4 alkyl group [optionally substituted by hydroxy, C.sub.1-3 alkoxy or trifluoromethyl or by a group NR.sub.8 R.sub.9 where NR.sub.8 R.sub.9 forms a saturated 5 to 7 membered ring optionally containing an additional heleroatom which is oxygen]; or R.sub.7 represents a phenylC.sub.1-2 alkyl group in which the phenyl portion is optionally substituted by 1 to 3 C.sub.1-3 alkyl or C.sub.1-3 alkoxy groups or halogen atoms. The compounds represented by formula (I) reduce intracellular calcium ion concentration by limiting transmembranal calcium ion influx and thus may be useful for the treatment of cardiovascular disorders such as hypertension.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.